Oluyemi Okupe Sells 11,581 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $28.50, for a total transaction of $330,058.50. Following the sale, the chief financial officer now owns 118,960 shares in the company, valued at $3,390,360. This represents a 8.87 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, April 2nd, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.26, for a total value of $338,860.06.
• On Monday, February 10th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $43.01, for a total transaction of $498,098.81.
• On Tuesday, February 4th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $38.92, for a total value of $450,732.52.

Hims & Hers Health Stock Down 4.8 %

Hims & Hers Health stock traded down $1.32 during trading hours on Monday, hitting $25.91. The stock had a trading volume of 10,805,858 shares, compared to its average volume of 15,362,967. The stock has a market capitalization of $5.76 billion, a P/E ratio of 58.89 and a beta of 1.65. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The stock's 50-day moving average price is $36.85 and its 200-day moving average price is $30.85.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC lifted its holdings in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after buying an additional 8,364,000 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after acquiring an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd bought a new stake in Hims & Hers Health in the fourth quarter worth about $41,104,000. Finally, Renaissance Technologies LLC boosted its holdings in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on HIMS shares. Canaccord Genuity Group raised their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Piper Sandler increased their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Leerink Partners raised their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Finally, Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Wednesday, April 2nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, Hims & Hers Health has an average rating of "Hold" and a consensus target price of $38.25.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.